Could a single pill tame bipolar depression and obesity together?

NCT ID NCT07699445

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether the drug lumateperone can improve mood and reduce inflammation in adults with bipolar depression who also have obesity. Over about six weeks, participants take lumateperone daily and undergo mood assessments and an MRI to estimate brain age. The goal is to see if the drug helps both depression and the physical effects of aging linked to obesity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lumateperone
What this could lead to
If successful, this could point toward a treatment that addresses both mood and weight-related inflammation in bipolar depression.
What could go wrong
This is a small, early-phase study with only 25 participants, so results may not apply broadly. Lumateperone may cause side effects like drowsiness or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR DEPRESSION DEPRESSED PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.